2024
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Epperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Evens A, Naik S, Kamdar M, Haverkos B, Karmali R, Farooq U, Vose J, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Advances 2024, 8: 5355-5364. PMID: 39189932, PMCID: PMC11568788, DOI: 10.1182/bloodadvances.2024013791.Peer-Reviewed Original ResearchBaseline CNS involvementCentral nervous system recurrenceHigh-grade B-cell lymphomaCentral nervous systemB-cell lymphomaCNS involvementCNS recurrenceIncidence of CNS recurrenceRisk of CNS recurrenceCentral nervous system involvementMulti-institutional seriesNon-GCB subtypeBone marrow involvementMulticenter retrospective studyCNS-IPIRisk factor analysisMarrow involvementMYC rearrangementNon-GCBPrimary therapyCD5 expressionAutologous transplantationSurvival outcomesNo significant differenceNOS patientsData-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
Komrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, Travaglino E, Al Ali N, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain A, Aguirre L, Tinsley-Vance S, Schwabkey Z, Chan O, Xie Z, Brunner A, Kuykendall A, Bennett J, Buckstein R, Bejar R, Carraway H, DeZern A, Griffiths E, Halene S, Hasserjian R, Lancet J, List A, Loghavi S, Odenike O, Padron E, Patnaik M, Roboz G, Stahl M, Sekeres M, Steensma D, Savona M, Taylor J, Xu M, Sweet K, Sallman D, Nimer S, Hourigan C, Wei A, Sauta E, D’Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate U, Sanz G, Efficace F, Gore S, Kim T, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang A, Foucar M, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht A, Ades L, Zeidan A, Della Porta M, Syndromes I. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. The Lancet Haematology 2024, 11: e862-e872. PMID: 39393368, DOI: 10.1016/s2352-3026(24)00251-5.Peer-Reviewed Original ResearchGenomic featuresData-driven approachTP53 inactivationGenomic heterogeneityEntity labelsGenetic featuresDel(7q)/-7Myelodysplastic syndromeGenomic profilingData scientistsMutated SF3B1Cluster assignmentComplex karyotypeRUNX1 mutationsModified Delphi consensus processDel(5qIsolated del(5qAcute myeloid leukemiaData-drivenDelphi consensus processMarrow blastsSpatially exploring RNA biology in archival formalin-fixed paraffin-embedded tissues
Bai Z, Zhang D, Gao Y, Tao B, Zhang D, Bao S, Enninful A, Wang Y, Li H, Su G, Tian X, Zhang N, Xiao Y, Liu Y, Gerstein M, Li M, Xing Y, Lu J, Xu M, Fan R. Spatially exploring RNA biology in archival formalin-fixed paraffin-embedded tissues. Cell 2024, 187: 6760-6779.e24. PMID: 39353436, PMCID: PMC11568911, DOI: 10.1016/j.cell.2024.09.001.Peer-Reviewed Original ResearchRNA biologyWhole-transcriptome sequencingMicroRNA regulatory networkSplicing dynamicsDeterministic barcodingRNA speciesRNA processingRNA variantsFFPE tissuesRegulatory networksTranscriptome sequencingSpliced isoformsNon-malignant cellsTumor clonal architecturesClonal architectureGene expressionCellular dynamicsRNAArchival formalin-fixed paraffin-embedded tissueMalignant subclonesFormalin-fixed paraffin-embedded (FFPEFFPE samplesParaffin-embedded (FFPEBiologyHuman lymphomasContemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])
Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, DeZern A, Efficace F, Fenaux P, Figueroa M, Garcia-Manero G, Gore S, Greenberg P, Griffiths E, Halene S, Hourigan C, Kim T, Kim N, Komrokji R, Kutchroo V, List A, Little R, Majeti R, Nazha A, Nimer S, Odenike O, Padron E, Patnaik M, Platzbecker U, Della Porta M, Roboz G, Sallman D, Santini V, Sanz G, Savona M, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Wei A, Xie Z, Xu M, Hasserjian R, Loghavi S. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Modern Pathology 2024, 37: 100615. PMID: 39322118, DOI: 10.1016/j.modpat.2024.100615.Peer-Reviewed Original ResearchLarge B‐cell lymphoma with mystery rearrangement: Applying Hi‐C to the detection of clinically relevant structural abnormalities
Prior D, Schmitt A, Louissaint A, Mata D, Massaro S, Nardi V, Xu M. Large B‐cell lymphoma with mystery rearrangement: Applying Hi‐C to the detection of clinically relevant structural abnormalities. British Journal Of Haematology 2024, 205: 1225-1229. PMID: 38924537, DOI: 10.1111/bjh.19611.Peer-Reviewed Original ResearchRare Drivers at Low Prevalence with High Cancer Effects in T-Cell and B-Cell Pediatric Acute Lymphoblastic Leukemia
Mandell J, Diviti S, Xu M, Townsend J. Rare Drivers at Low Prevalence with High Cancer Effects in T-Cell and B-Cell Pediatric Acute Lymphoblastic Leukemia. International Journal Of Molecular Sciences 2024, 25: 6589. PMID: 38928295, PMCID: PMC11203805, DOI: 10.3390/ijms25126589.Peer-Reviewed Original ResearchGenomic analysisPediatric acute lymphoblastic leukemiaCancer effectsAcute lymphoblastic leukemiaT cellsTherapeutic targetSomatic substitutionsRare driversB-ALLLymphoblastic leukemiaEpistatic effectsT-cell ALL patientsMutational contributionsMutated genesCancer phenotypeMutated formDevelopment of leukemiaLow prevalenceB-cell lineageDisease mechanismsMutationsPrecision therapeuticsTherapeutic opportunitiesT-ALLALL patientsLiquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results
Mata D, Lee J, Shanmugam V, Marcus C, Schrock A, Williams E, Ritterhouse L, Hickman R, Janovitz T, Patel N, Kroger B, Ross J, Mirza K, Oxnard G, Vergilio J, Elvin J, Benhamida J, Decker B, Xu M. Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology 2024, 84: 1224-1237. PMID: 38422618, DOI: 10.1111/his.15168.Peer-Reviewed Original ResearchConceptsNon-Hodgkin's lymphomaPlasma-cell neoplasmsAcute myeloid leukemiaCirculating tumor DNAHodgkin lymphomaMyelodysplastic syndromeHaematopoietic neoplasmsNext-generation sequencingTissue-based NGSMaximum somatic allele frequencyFoundationOne Liquid CDxTherapy-resistant clonesRelevant genomic alterationsPositive percent agreementPotential clinical utilityLymphoid malignanciesTumor DNAMyeloid leukemiaPlasma-cellsTissue biopsiesGenomic alterationsPathogenic alterationsLiquid biopsyMolecular profilingTP53PD-1H/VISTA mediates immune evasion in acute myeloid leukemia
Kim T, Han X, Hu Q, Vandsemb E, Fielder C, Hong J, Kim K, Mason E, Plowman R, Wang J, Wang Q, Zhang J, Badri T, Sanmamed M, Zheng L, Zhang T, Alawa J, Lee S, Zeidan A, Halene S, Pillai M, Chandhok N, Lu J, Xu M, Gore S, Chen L. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia. Journal Of Clinical Investigation 2024, 134 PMID: 38060328, PMCID: PMC10836799, DOI: 10.1172/jci164325.Peer-Reviewed Original ResearchGenetics and pathologic landscape of lineage switch of acute leukemia during therapy
Zhou T, Curry C, Khanlari M, Shi M, Cui W, Peker D, Chen W, Wang E, Gao J, Shen Q, Xie W, Jelloul F, King R, Yuan J, Wang X, Zhao C, Obiorah I, Courville E, Nomura E, Cherian S, Xu M, Burack W, Liu H, Jabbour E, Takahashi K, Wang W, Wang S, Khoury J, Medeiros L, Hu S. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood Cancer Journal 2024, 14: 19. PMID: 38272888, PMCID: PMC10810851, DOI: 10.1038/s41408-024-00983-2.Peer-Reviewed Original Research
2023
Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype
Verma A, Liburd S, Tobias Z, Isufi I, Pober J, Xu M. Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype. Blood 2023, 142: 2075. DOI: 10.1182/blood-2023-184963.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaPre-treatment biopsiesVenular endothelial cellsLarge B-cell lymphomaMemory T cellsHigh endothelial venulesT cellsB-cell lymphomaVCAM-1E-selectinICAM-1Endothelial cellsChimeric antigen receptor T-cell therapyL-selectinPre-treatment tumor biopsiesEffector memory T cellsCentral memory T cellsCAR T-cell therapyCell therapyHEV endothelial cellsInflamed lymph nodesT-cell infiltratesT cell exhaustionT-cell therapyT-cell homingIRF8 in Conjunction With CD123 and CD20 to Distinguish Lupus Erythematosus Panniculitis From Subcutaneous Panniculitis-like T-Cell Lymphoma
Wong J, Roy S, McNiff J, Xu M. IRF8 in Conjunction With CD123 and CD20 to Distinguish Lupus Erythematosus Panniculitis From Subcutaneous Panniculitis-like T-Cell Lymphoma. The American Journal Of Surgical Pathology 2023, 47: 1425-1431. PMID: 37767989, DOI: 10.1097/pas.0000000000002133.Peer-Reviewed Original ResearchConceptsSubcutaneous panniculitis-like T-cell lymphomaLupus erythematosus panniculitisPanniculitis-like T-cell lymphomaCase of SPTCLT-cell lymphomaPlasmacytoid dendritic cell differentiationPlasmacytoid dendritic cellsExpression of IRF8Dendritic cell differentiationCharacteristic curve analysisImportant clinical implicationsRegulatory factor 8Dendritic cellsCutaneous biopsyLymphoid aggregatesDiagnostic challengeImmunohistochemical panelImmunohistochemical expressionCD123CD20Distinct patientsClinical implicationsSubcutaneous fatDiagnostic testsPositive markersAn agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS)
Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kuchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). Blood Advances 2023, 7: 2709-2714. PMID: 36260702, PMCID: PMC10333740, DOI: 10.1182/bloodadvances.2022008747.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsIRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression
Tang H, Panse G, Braddock D, Perincheri S, Xu M, McNiff J. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression. Journal Of Cutaneous Pathology 2023, 50: 595-600. PMID: 37082914, DOI: 10.1111/cup.14439.Peer-Reviewed Original ResearchConceptsBlastic plasmacytoid dendritic cell neoplasmPlasmacytoid dendritic cell neoplasmDendritic cell neoplasmPunch biopsy specimenBiopsy specimenCell neoplasmsCase of BPDCNUseful markerTumor cellsTCL-1 expressionAtypical mononuclear cellsBone marrow involvementDiffuse dermal infiltrateDendritic cell lineagePotential diagnostic pitfallRegulatory factor 8TCL-1BPDCN casesCD123 expressionMarrow involvementDermal infiltrateCutaneous nodulesMyelodysplastic syndromeSkin nodulesMononuclear cellsHigh-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq
Liu Y, DiStasio M, Su G, Asashima H, Enninful A, Qin X, Deng Y, Nam J, Gao F, Bordignon P, Cassano M, Tomayko M, Xu M, Halene S, Craft J, Hafler D, Fan R. High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq. Nature Biotechnology 2023, 41: 1405-1409. PMID: 36823353, PMCID: PMC10567548, DOI: 10.1038/s41587-023-01676-0.Peer-Reviewed Original Research
2022
Liquid Biopsy-Based Next-Generation Sequencing Is an Alternative to Tissue Molecular Profiling of Lymphoid, Plasma-Cell, and Myeloid Neoplasms
Mata D, Lee J, Decker B, Shanmugam V, Marcus C, Tukachinsky H, Schrock A, Patel N, Ross J, Oxnard G, Vergilio J, Mirza K, Xu M, Benhamida J. Liquid Biopsy-Based Next-Generation Sequencing Is an Alternative to Tissue Molecular Profiling of Lymphoid, Plasma-Cell, and Myeloid Neoplasms. Blood 2022, 140: 1205-1207. DOI: 10.1182/blood-2022-159106.Peer-Reviewed Original ResearchNot only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia
Mandell J, Fisk J, Cyrenne E, Xu M, Cannataro V, Townsend J. Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia. Leukemia 2022, 36: 2931-2933. PMID: 36369483, PMCID: PMC9712081, DOI: 10.1038/s41375-022-01752-5.Peer-Reviewed Original ResearchDifferences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms
Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia 2022, 36: 2934-2938. PMID: 36335264, DOI: 10.1038/s41375-022-01754-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsFinding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 2022, 36: 2939-2946. PMID: 36266326, DOI: 10.1038/s41375-022-01724-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsBreast implant‐associated anaplastic large‐cell lymphoma: A series of two case reports diagnosed by cytopathology
Hrones M, Harigopal M, Xu M, Abi‐Raad R. Breast implant‐associated anaplastic large‐cell lymphoma: A series of two case reports diagnosed by cytopathology. Diagnostic Cytopathology 2022, 51: e25-e27. PMID: 36066320, DOI: 10.1002/dc.25052.Peer-Reviewed Original ResearchConceptsBreast implant-associated anaplastic large cell lymphomaImplant-associated anaplastic large cell lymphomaRare T-cell lymphomaAnaplastic large cell lymphomaPeri-implant effusionT-cell lymphomaLarge cell lymphomaCommon presentationDefinite treatmentBetter prognosisCase reportCytopathologic findingsCytopathologic analysisImplant removalEarly diagnosisFluid collectionBreast implantsCytopathological examinationLymphomaReportPatientsPrognosisEffusionDiseaseDiagnosisResponse to Letter to the Editor: IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias but does not Discriminate Between Monoblasts and Plasmacytoid Dendritic Cells
Xu ML, Katz SG. Response to Letter to the Editor: IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias but does not Discriminate Between Monoblasts and Plasmacytoid Dendritic Cells. The American Journal Of Surgical Pathology 2022, 46: 1739-1739. PMID: 36040049, DOI: 10.1097/pas.0000000000001961.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply